Wayne Furman, MD

Wayne L. Furman, MD

Member, St. Jude Faculty
Interim Division Director, Solid Tumor Division

Departments

Oncology

Divisions

Solid Tumor

Contact Information

Wayne Furman, MD
Oncology
MS 260, Room C6016
St. Jude Children's Research Hospital
262 Danny Thomas Place
Memphis, TN 38105-3678
Email: wayne.furman@stjude.org
Phone: (901) 595-2403

Education

BS - Allegheny College, Meadville, Pennsylvania
MD - Ohio State University College of Medicine, Columbus, Ohio

Research Interests

  • Phase I clinical trials
  • Therapy of Neuroblastoma
  • Therapy of childhood liver tumors
  • Cytokine use in the treatment of cancer

Selected Publications

Furman WL, Crews KR, Billups C, Wu J, Gajjar AJ, Daw NC, Patrick CC, Rodriguez-Galindo C, Stewart CF, Dome JS, Panetta JC, Houghton PJ, Santana VM. Cefixime Allows Greater Dose-Escalation of Oral Irinotecan: A Phase I Study in Pediatric Patients with Refractory Solid Tumors. J Clin Oncol 24(4):563-70, 2006.

Hinds PS, Drew D, Oakes LL et al: End-of-Life Care Preferences of Pediatric Patients With Cancer. J Clin Oncol 23(36): 9146-54, 2005.

McGregor LM, Rao BN, Davidoff AM, Billups CA, Hongeng S, Santana VM, Hill DA, Fuller C, Furman WL. The impact of early resection of primary neuroblastoma on the survival of children older than 1 year of age with stage 4 disease: the St. Jude Children's Research Hospital Experience. Cancer 15;104(12):2837-46, 2005.

Daw NC, Furman WL, Stewart CF et al: Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group Study. J Clin Oncol 23:6172-6180, 2005.

Sanders RP, Furman WL. Familial adenomatous polyposis in two brothers with hepatoblastoma: Implications for diagnosis and screening. Pediatr Blood Cancer 2005 (ahead of print).

Rodriguez-Galindo C, Crews KR, Stewart CF et al: Phase I study of the combination of topotecan and irinotecan in children with refractory solid tumors. Cancer Chemother Pharmacol 2005 (in press).

Santana VM, Furman WL, Billups CA et al: Improved response in high-risk neuroblastoma with protracted topotecan administration using a pharmacokinetically guided dosing approach. J Clin Oncol 23:4039-4047, 2005

McCarville MB, Adelman CS, Li C et al: Typhlitis in childhood cancer. Cancer 104:380-387, 2005.

Inaba H, Handgretinger R, Furman W et al: Allogeneic graft-versus-hepatoblastoma effect. Pediatr Blood Cancer, 2005.

Navid F, Furman WL, Fleming M et al: The feasibility of adjuvant interferon alpha-2b in children with high-risk melanoma. Cancer 103:780-787, 2005.

Davidoff AM, Corey BL, Hoffer FA et al: Radiographic assessment of resectability of locoregional disease in children with high-risk neuroblastoma during neoadjuvant chemotherapy. Pediatr Blood Cancer 44:158-162, 2005.

Hayes-Jordan AA, Daw NC, Furman WL, Hoffer FA, Shochat SJ. Tumor recurrence at thoracostomy tube insertion sites: a report of two pediatric cases. J Pediatr Surg 39(10):1565-7, 2004.

Daw NC, Santana VM, Iacono LC, Furman WL, Hawkins DR, Houghton PJ, Panetta JC, Gajjar AJ, Stewart CF. Phase I and pharmacokinetic study of topotecan administered orally once daily for 5 days for consecutive weeks to pediatric patients with refractory solid tumors. J Clin Oncol 22: 829-837, 2004.

Wagner LM, Billups CA, Furman WL, Rao BN, Santana VM. Combined use of erythropoietin and granulocyte colony-stimulating factor does not decrease blood transfusion requirements during induction therapy for high-risk neuroblastoma: a randomized control trail. J Clinc Oncol 22:1886-1893, 2004.

Aquino VM, Weitman SD, Winick NJ, Blaney S, Furman WL, Kepner JL, Bonate P, Krailo M, Qu W, Berstein M. Phase I trail of tirapazamine and cyclophosphamide in children with refractory solid tumors: a pediatric oncology group study. J Clinc Oncol 22(8): 1413-1419, 2004.

Hill DA, Dehner LP, Gow KW et al. Perianal rhabdomyosarcoma presenting as a perirectal abscess: A report of 11 cases. J Pediatr Surg 37:576-581, 2002.

Furman WL, Stewart CF, Kirstein M, Kepner JL, Berstein ML, Kung F, et al. A protracted intermittent schedule of topotecan in children with refractory acute leukemia: a pediatric oncology group study. J Clin Onc 20 (6):1617-1624, 2002.

McCarville MB, Ross MB, Rao BN, Furman WL. Sonographic appearance of appendicitis in a neutropenic pediatric patient after inversion appendectomy. Pediatr Radiol 31:578-580, 2001.

Kaste SC, Rodriguez-Galindo C, Furman WL, Langston J, Thompson SJ. Imaging aspects of neurologic emergencies in children treated for non-CNS malignancies. Pediatr Radiol 30(8):558-64; 2001.

Wagner LM, Furman WL. Haemopoietic growth factors in pediatric oncology: a review of the literature. Pediatr Drugs 3(3):195-217, 2001.

Sandlund JT, Murphy SB, Santana VM, Behm F, Jones D, Berard CW, Furman WL, Ribeiro R, Crist WM, Greenwald C, Chen G, Walter A, Pui CH. CNS involvement in children with newly diagnosed non-Hodgkin’s lymphoma. J Clin Oncol 18(16):3018-3024, 2000.

Rodriguez-Galindo C, Radomski K, Stewart CF, Furman W, Santana VM, Houghton PJ. Clinical use of topoisomerase I inhibitors in anticancer treatment. Med Pediatr Oncol 35(4)385-402, 2000.

Hinds PS, Oakes L, Quargnenti A, Furman W, Bowman L, Gilger E, Gattuso J, Martinson I, Yi KH, Drew D. An international feasibility study of parental decision making in pediatric oncology. Oncol Nurs Forum 27(8):1233-1243, 2000.

Hinds PS, Oakes L, Furman W, Quargnenti A, Olson MS, Foppiano P, Srivastava DK. End of life decision making by adolescents, parents, and healthcare providers in pediatric oncology. Cancer Nurs 24(2):122-135, 2000.

Ma MK, Zamboni WC, Radomski KM, Furman WL, Santana VM, Houghton PJ, Hanna SK, Smith AK, Stewart CF. Pharmacokinetics of irinotecan and its metabolites SN-38 and APC in children with recurrent solid tumors after protracted low-dose irinotecan. Clin Cancer Res 6:813-819, 2000.

Haliloglu M, Hoffer FA, Gronemeyer SA, Furman WL, Shochat SJ. 3D gadolinium-enhanced MRS: evaluation of hepatic vasculature in children with hepatoblastoma. J Magn Reson Imag 11:65-68, 2000.

 

Last update: March 2006

 

Email This Article Email This Article   |   Print Print